29913-51-7

Usage

Uses

Used in Pharmaceutical Industry:
4-hydroxy-.alpha.,.alpha.-dimethyl-Benzeneacetic acid is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure allows it to serve as a key component in the development of new medications.
Used in Anti-inflammatory and Analgesic Applications:
4-hydroxy-.alpha.,.alpha.-dimethyl-Benzeneacetic acid is studied for its potential anti-inflammatory and analgesic properties. Its ability to reduce inflammation and alleviate pain makes it a promising candidate for the development of new treatments for conditions such as arthritis and other inflammatory disorders.
Used in Fragrance and Flavoring Industry:
4-hydroxy-.alpha.,.alpha.-dimethyl-Benzeneacetic acid is utilized in the production of fragrances and flavorings. Its unique chemical properties contribute to the creation of distinct scents and tastes, making it a valuable ingredient in the formulation of various consumer products.

Upstream product

• 55770-61-1 2-(4-Hydroxyphenyl)-2-methylpropionitrile 
• 5351-07-5 2-(4-methoxy-phenyl)-2-methyl-propionitrile 
• 108-95-2 phenol 
• 80-05-7 BPA 
• 6274-50-6 methyl 2-(4-methoxyphenyl)-2-methylpropanoate 
• 2955-46-6 2-(4-methoxyphenyl)-2-methylpropanoic acid 

Downstream Products

• 123342-40-5 methyl 2-(4-hydroxyphenyl)-2-methylpropanoate 
• 731015-44-4 methyl 2-(3-formyl-4-hydroxyphenyl)-2-methylpropanoate 
• 731015-45-5 methyl 2-(3-bromo-5-formyl-4-hydroxy-phenyl)-2-methyl-propionate 
• 909036-40-4 2-(4-benzyloxy-3-bromo-5-formyl-phenyl)-2-methyl-propionic acid methyl ester 
• 909036-41-5 2-[6-benzyloxy-3'-(tert-butoxycarbonylamino-methyl)-5-formyl-biphenyl-3-yl]-2-methyl-propionic acid methyl ester 
• 909036-42-6 2-[6-benzyloxy-3'-(tert-butoxycarbonylamino-methyl)-5-ethynyl-biphenyl-3-yl]-2-methyl-propionic acid methyl ester 
• 909036-45-9 2-[3'-aminomethyl-5-(4-amino-1H-pyrrolo[3,2-c]pyridin-2-yl)-6-hydroxy-biphenyl-3-yl]-2-methyl-propionic acid 
• 909036-44-8 2-[6-benzyloxy-3'-(tert-butoxycarbonylamino-methyl)-5-(4-chloro-1H-pyrrolo[3,2-c]pyridin-2-yl)-biphenyl-3-yl]-2-methyl-propionic acid 
• 1421838-11-0 N-(bis(4-fluorophenyl)methyl)-2-(4-hydroxyphenyl)-2-methylpropanamide 
• 152270-53-6 ethyl 2-(4-hydroxyphenyl)-2-methylpropanoate 
• 871822-60-5 (2S)-{2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]-2-methylpropionylamino}succinamide 
• 871822-53-6 methyl 2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-5'-cyano-6,2'-dimethoxybiphenyl-3-yl]-2-methylpropanoate 
• 731015-35-3 2-[5-(5-carbamimidoyl-1H-benzimidazol-2-yl)-6,2'-dihydroxy-5'-sulfamoylbiphenyl-3-yl]-2-methylpropionic acid 
• 731016-03-8 methyl 2-(3-bromo-5-formyl-4-methoxyphenyl)-2-methyl-propionate 

Relevant academic research and scientific papers

Comparative toxicity reduction potential of UV/sodium percarbonate and UV/hydrogen peroxide treatments for bisphenol A in water: An integrated analysis using chemical, computational, biological, and metabolomic approaches

Bisphenol A (BPA) is a common industrial chemical with significant adverse impacts on biological systems as an environmental contaminant. UV/hydrogen peroxide (UV/H2O2) is a well-established technology for BPA treatment in water while UV/sodium percarbonate (UV/SPC) is an emerging technology with unclear biological impacts of treated effluent. Therefore, in this study, the toxicity evaluation of BPA solution treated with UV/H2O2 and UV/SPC was preformed and compared based on transformation products (TPs) profile, quantitative structure-activity relationship (QSAR), Escherichia coli (E. coli) toxicity assays, and metabolomic analysis. TPs with hydroxylation, double-ring split, and single-ring cleavage were generated from BPA during the treatments with both technologies, but TPs with quinonation were specifically detected in UV/H2O2 treated solution at the UV dose of 1470 mJ cm?2. QSAR prediction based on TPs profile (excluding benzoquinone TPs) suggested that UV/H2O2 and UV/SPC treatments of BPA may increase matrix toxicity due to the formation of multi-hydroxylated TPs; however decreased bioaccumulation potential of all TPs may mitigate the increase of toxicity by reducing the chance of TPs to reach the concentration of toxicity threshold. In vivo assays with E. coli showed inhibited cell growth, arrested cell cycle, and increased cell death in BPA solution treated with UV/H2O2 at the UV dose of 1470 mJ cm?2. Metabolomic analysis indicated that BPA solution treated with UV/H2O2 at UV dose of 1470 mJ cm?2 impacted E. coli metabolism differently than other solutions with unique inhibition on glycerolipid metabolism. Moreover, BPA interfered in various metabolic pathways including alanine, aspartate and glutamate metabolism, starch and sucrose metabolism, pentose phosphate pathway, and lysine degradation, which were mitigated after the treatments. UV/SPC showed advantage over UV/H2O2 of attenuated impact on butanoate metabolism with UV irradiation. This study has generated valuable data for better understanding of biological impacts of BPA and its solutions treated with UV/H2O2 or UV/SPC, thus providing insights for their application prospect for water and wastewater treatment.

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-reiated orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

Falcipain inhibitors: Optimization studies of the 2-pyrimidinecarbonitrile lead series

Falcipain-2 and falcipain-3 are papain-family cysteine proteases of the malaria parasite Plasmodium falciparum that are responsible for host hemoglobin hydrolysis to provide amino acids for parasite protein synthesis. Different heteroarylnitrile derivatives were studied as potential falcipain inhibitors and therefore potential antiparasitic lead compounds, with the 5-substituted-2- cyanopyrimidine chemical class emerging as the most potent and promising lead series. Through a sequential lead optimization process considering the different positions present in the initial scaffold, nanomolar and subnanomolar inhibitors at falcipains 2 and 3 were identified, with activity against cultured parasites in the micromolar range. Introduction of protonable amines within lead molecules led to marked improvements of up to 1000 times in activity against cultured parasites without noteworthy alterations in other SAR tendencies. Optimized compounds presented enzymatic activities in the picomolar to low nanomolar range and antiparasitic activities in the low nanomolar range.

CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.

Potent 4-amino-5-azaindole factor VIIa inhibitors

The 4-amino-5-azaindole as an amidino-benzimidazole replacement is described. A series of potent and selective analogs were discovered and showed desirable ex vivo efficacy as measured by PT.

FACTOR VIIA INHIBITOR

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders

Anti-atherosclerotic diaryl compounds

The present invention is concerned with diaryl compounds of formula (l) and their use in medical therapy, particularly in the prophylaxis or treatment of a clinical condition for which an ACAT inhibitor is indicated, such as hyperlipidaema or atherosclerosis. The invention also relates to pharmaceutical compositions and processes for the preparation of compounds according to the invention. STR1

Structural Evolution and Pharmacology of a Novel Series of Triacid Angiotensin II Receptor Antagonists

cis-4-(4-Phenoxy)-1--1H-imidazol-1-yl>octyl>-L-proline derivatives represent a novel class of potent nonpeptide angiotensin II (Ang II) receptor antagonists.These compounds evolved from directed structure-activity rel

Formation of hydroxy aryl carboxylic acids and esters

Hydroxy aryl carboxylic acids are formed by reacting a hydroxy aryl compound, such as phenol, with a ketone, such as acetone and carbon monoxide in the presence of a strong acid. The preferred embodiment is the one step formation of 2-methyl-2-(p-hydroxyp